Coherus BioSciences, Inc. (CHRS)

1.9000 -0.2200 (-10.38%) 收市：04:00PM EDT

Coherus BioSciences, Inc.

333 Twin Dolphin Drive
Suite 600
Redwood City, CA 94065
United States
650 649 3530
https://www.coherus.com

版塊: Healthcare
行業: Biotechnology
全職員工: 249

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Dennis M. Lanfear	Chairman, President & CEO	1.82M	179.98k	1955
Mr. Bryan J. McMichael	Interim CFO, Principal Financial and Accounting Officer, SVP-Accounting & Corporate Controller	615.07k	無	1979
Mr. Paul Reider	Chief Commercial Officer	854.06k	無	1970
Mr. Richard L. Hameister	Chief Technical Officer	無	無	無
Ms. Jami Taylor	Vice President of Investor Relations	無	無	無
Ms. Andy Rittenberg	Executive Vice President of General Counsel	無	無	無
Cheston Turbyfill	Vice President of Communications	無	無	無
Mr. Scott Saywell	Executive Vice President of Corporate Development	無	無	無
Ms. Rebecca Sunshine	Chief Human Resources Officer	無	無	1963
Mr. Michael Chen	Senior Vice President of Commercial Analytics & Trade	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

公司管治

截至 2024年5月1日 止，Coherus BioSciences, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：7；董事會：6；股東權利：8；現金賠償：8。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。